Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 4 November 1983:
Vol. 222. no. 4623, pp. 512 - 515
DOI: 10.1126/science.6353579
Prev | Table of Contents | Next

Articles

Science, Vol 222, Issue 4623, 512-515
Copyright © 1983 by American Association for the Advancement of Science

articles

Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies

DA Vallera, RC Ash, ED Zanjani, JH Kersey, TW LeBien, PC Beverley, DM Neville Jr, and RJ Youle

Three new reagents that react against human T cells were synthesized by covalently linking the toxin ricin to monoclonal antibodies recognizing differentiation antigens on the surface of T lymphocytes. Each of these immunotoxins selectively inhibited T-cell proliferation when the cells were incubated in the presence of lactose. Multipotent human stem cells were inhibited only at much higher concentrations. Mixtures of all three immunotoxins were more effective than any one alone. These reagents have the potential for preventing graft-versus-host disease in man.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
D. A. Todhunter, W. A. Hall, E. Rustamzadeh, Y. Shu, S. O. Doumbia, and D. A. Vallera (2004)
Protein Eng. Des. Sel. 17, 157-164
   Abstract »    Full Text »    PDF »
Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
C. Li, W. A. Hall, N. Jin, D. A. Todhunter, A. Panoskaltsis-Mortari, and D. A. Vallera (2002)
Protein Eng. Des. Sel. 15, 419-427
   Abstract »    Full Text »    PDF »
Targeting Urokinase-Type Plasminogen Activator Receptor on Human Glioblastoma Tumors With Diphtheria Toxin Fusion Protein DTAT.
D. A. Vallera, C. Li, N. Jin, A. Panoskaltsis-Mortari, and W. A. Hall (2002)
J Natl Cancer Inst 94, 597-606
   Abstract »    Full Text »    PDF »
Long-term Effects of Ricin-mAb 35 on Extraocular Muscles of Rabbits: Potential Treatment for Strabismus.
S. P. Christiansen, D. Peterson, T. To, R. Youle, and L. McLoon (2002)
Invest. Ophthalmol. Vis. Sci. 43, 679-685
   Abstract »    Full Text »    PDF »
A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
Y. V. J. M. van Oosterhout, L. van Emst, A. V. M. B. Schattenberg, W. J. M. Tax, D. J. Ruiter, H. Spits, F. M. Nagengast, R. Masereeuw, S. Evers, T. de Witte, et al. (2000)
Blood 95, 3693-3701
   Abstract »    Full Text »    PDF »
Purging of Mammary Carcinoma Cells During Ex Vivo Culture of CD34+ Hematopoietic Progenitor Cells With Recombinant Immunotoxins.
A. Spyridonidis, M. Schmidt, W. Bernhardt, A. Papadimitriou, M. Azemar, W. Wels, B. Groner, and R. Henschler (1998)
Blood 91, 1820-1827
   Abstract »    Full Text »    PDF »
Redesigning nature's poisons to create anti-tumor reagents.
E. Vitetta, R. Fulton, R. May, M Till, and J. Uhr (1987)
Science 238, 1098-1104
   Abstract »    PDF »
Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity.
L Greenfield, V. Johnson, and R. Youle (1987)
Science 238, 536-539
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)